Tikun Olam’s award-winning premium cannabis products are backed by years of peer-reviewed scientific research and unprecedented clinical data collection, which has shown to deliver symptomatic relief to those suffering from specific conditions such as cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy, to name a few.
At the 2017 Canadian Cannabis Awards held November 30 in Toronto, Tikun strains took First place in three categories: Top High THC Flower (Eran Almog), Top High CBD Flower (Avidekel), and Top High CDB Oil (Avidekel), in addition to placing Second in Top Hybrid Flower (Midnight). Tikun’s full line of proprietary strain products--from flower, vape, topicals and tinctures--will be available in Washington DC beginning in 2018.
“Alternative Solutions is thrilled to be Tikun Olam’s exclusive partner in DC,” says Matt Lawson-Baker, COO of Alternative Solutions. “We look forward to making Tikun's products available at all DC dispensaries, giving access to these clinically proven strains to the more than 5,600 registered MMJ patients in Washington DC.”
The new five-year deal with Alternative Solutions is the latest in a series of licensing agreements struck since Tikun’s U.S. launch in 2015 in Delaware. The recent announcement with the MariMed cannabis network will introduce Tikun’s exclusive strains and products in medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun™ products also launched in Nevada in March 2017 and in Washington State in November.
“Tikun Olam is delighted with our partnership with Alternative Solutions,” says Tikun CEO Bernard Sucher. “Its cultivation and manufacturing operations will make it possible for Tikun to serve every single patient in a single jurisdiction--a first for us and something we hope to accomplish within every U.S. state."
About Tikun Olam
Tikun Olam (“repair the world” in Hebrew) is the world’s leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. Operating as a commercial venture for over 10 years, Tikun Olam’s products have been used since 2010 in ongoing clinical trials in Israel’s regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn’s Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy.
Through this access to patients, medical personnel and data collection, Tikun Olam has developed multiple proprietary strains, including the first-ever, high-CBD, “high-less” strain Avidekel™, its popular high-THC strain Alaska™, and its “one-to-one” CBD/THC strain Midnight™. Tikun Olam’s U.S. operations, established in 2015 as T.O. Global LLC, is a joint venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar partnerships in Canada (TSX: LEAF), Australia, United Kingdom and South Africa, all in support of its global mission to educate the traditional medical community and its patients on the applications of cannabis as a scientifically proven wellness product. Visit www.tikunolamusa.com, and follow us on Facebook, Twitter, and Instagram.
About Alternative Solutions
Montana Apocathary d/b/a Alternative Solutions is one of eight current license holders (out of an allocated 10 licenses) for the cultivation, processing and distribution of cannabis within the District of Columbia. Alternative Solutions is licensed to distribute medical cannabis products to all licensed MMJ dispensaries within the District, which currently number five, expected to rise to seven in 2018.